New Drug Application

Lasmiditan Effective in Phase 3 Trial for Acute Migraine

Lasmiditan Effective in Phase 3 Trial for Acute Migraine

By

Eli Lily announced positive results from a Phase 3 trial of their first-in-class drug lasmiditan for the acute treatment of migraine.

FDA Policy Seeks to Increase Number of Generics on Market

FDA Policy Seeks to Increase Number of Generics on Market

By

The FDA has announced a new policy to expedite reviews of generic drug applications in cases where competition is limited.

FDA Approves Zilretta NDA for Knee Osteoarthritis

FDA Approves Zilretta NDA for Knee Osteoarthritis

The Food and Drug Administration has accepted for review the New Drug Application for Zilretta for the treatment of patients with osteoarthritis of the knee.

Sign Up for Free e-Newsletters